drugset / Trial / NCT06062277
COlchicine iN Circulating Inflammatory Markers After StrokE (CONCISE)
Phase 2
Unknown
91 enrolled
University College Dublin
Mater Misericordiae University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this phase 2, before-and-after interventional study is to investigate the effect of colchicine treatment on serum biomarkers of inflammation in patients with a history of stroke and atherosclerosis. Participants meeting inclusion criteria will have blood samples drawn at baseline, will be dispensed colchicine 0.5mg daily for a treatment period of 30 days and have blood samples drawn again at follow-up. All blood samples will be analysed for a panel of inflammatory blood markers and the change in blood inflammatory markers from baseline to end of treatment will be calculated.
Timeline
- Start
- 2023-10
- Primary completion
- 2024-10
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Colchicine | Small molecule | 0.5 mg | Oral |